• AtriCure Q1 2026 earnings call drew management speakers Michael Carrel, president and CEO, and Angela Wirick, CFO, with analysts from Canaccord Genuity, Piper Sandler, BTIG, JPMorgan, Needham, Stifel, Citizens JMP, Freedom Capital Markets.
• Revenue reached $141 million, up 14.3% year over year, with adjusted EBITDA of $17.1 million versus $8.8 million; net income was about $100,000, with EPS and adjusted EPS both $0.
• Guidance held for revenue of $600 million-$610 million and adjusted EBITDA of $80 million-$82 million, citing early-year conservatism, continued MIS ablation and international headwinds, mix-driven gross margin benefit that may not persist, and incremental R&D tied to faster BoxX-NoAF enrollment.
• BoxX-NoAF trial enrollment reached about 300 patients, tracking about a year ahead of plan with full enrollment now expected around end of year; management flagged potential late-breaker timing around AATS 2027 given 30-day follow-up and adjudication.
• PFA program completed first-in-human work in Australia with additional 30-40 patients planned in Europe, targeting FDA submission later this year and an IDE trial start next year; STS concomitant Afib treatment quality metric expected to take effect in 2027, with management pointing to potential ablation penetration lift from about 35% toward 80%-90% over three to five years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AtriCure Inc. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.